Stone, HB, McBride, WH, Colema, CN. Modifying normal tissue damage post-irradiation. Report of Workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland. Rad Res 2000; 157: 204–223.
Anscher, MS, Chen, L, Rabbani, Z et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62: 255–259.
De Jaeger, K, Seppenwoolde, Y, Kampinga, H, Boersma, LJ, Belderbos, JS, Lebesque, JV. Significance of plasma transforming growth factor-β levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1378–1387.
Anscher, MS, Kong, FM, Andrews, K et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis 1998. Int J Radiat Oncol Biol Phys 1998; 41: 1029–1035.
Chen, J, Williams, J, Ding, I et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002; 12: 26–33.
Ishii, Y, Kitamura, S. Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. Eur Respir J 1999; 13: 733–738.
Chen, Y, Hyrien, O, Williams, J, Okunieff, P, Smudzin, T, Rubin, P. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2005; 62: 260–266.
Baluna, RG, Eng, TY, Thomas, CR. Adhesion molecules in radiotherapy. Radiat Res 2006; 166: 819–831.
Villani, F, Dell'Oca, I, De Maria, P et al. Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin’s disease. Anticancer Res 1999; 19: 4475–4480.
Abratt, RP. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 2002; 35: 103–110.
Finkelstein, J, Johnston, CJ, Baggs, R, Rubin, P. Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys 1994; 28: 621–631.
Roman, J. Extracellular matrix and lung inflammation. Immunol Res 1996; 15: 163–178.
Vignola, AM, Chanez, P, Chiappara, G et al. Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases. Clin Exp Immunol 1996; 106: 114–119.
Ruoslahti, E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999; 76: 1–20.
Pankov, R, Yamada, KM. Fibronectin at a glance. J Cell Sci 2002; 115: 3861–3863.
Saba, TM, Jaffe, E. Plasma fibronectin (opsonic glycoprotein): its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am J Med 1980; 68: 577–594.
Briggs, SL. The role of fibronectin in fibroblast migration during tissue repair. J Wound Care 2005; 14: 284–287.
Romberger, DJ. Molecules in focus - fibronectin. Int J Biochem Cell Biol 1997; 29: 939–943.
Zerlauth, G, Wolf, G. Plasma fibronectin as a marker for cancer and other diseases. Am J Med 1984; 77: 685–689.
Hegele, A, Heidenreich, A, Kropf, J et al. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma. Tumour Biol 2004; 25: 111–116.
Ruelland, A, Kerbrat, P, Clerc, C, Legras, B, Cloarec, L. Level of plasma fibronectin in patients with breast cancer. Clin Chimica Acta 1988; 178: 283–287.
Hegele, A, Varga, Z, von Knobloch, R, Olbert, P, Kropf, J, Hofmann, R. Cellular fibronectin plasma and urine levels in human bladder cancer. Eur Urology 2002; 1: 76–77.
Ruiz, MG, Prieto, PJ, Veiga de Cabo, J et al. Plasma fibronectin as a marker of sepsis. Int J Infect Dis 2004; 8: 236–243.
Pence, S, Yilmaz, G, Yilmaz, N et al. Determination of plasma fibronectin and serum C-reactive protein in patients with cerebrovascular events. Int J Clin 2003; 57: 91–95.
Ohke, M, Tada, S, Kataoka, M, Matsuo, K, Nabe, M, Harada, M. Plasma fibronectin in asthmatic patients and its relation to asthma attack. Acta Med Okayama 2001; 55: 91–96.
Simo, R, Segura, RM, Garcia-Pascual, L et al. Fibronectin and diabetes mellitus: the factors that influence its plasma concentrations and its usefulness as a marker of late complications. Med Clin 1999; 112: 45–50.
Ostlund, E, Hansson, LO, Bremme, K. Fibronectin is a marker for organ involvement and may reflect the severity of preeclampsia. Hypertens Pregnancy 2001; 20: 79–87.
Liu, XS, Luo, ZH, Yang, ZC, Li, AN. Clinical significance of the changes in serum fibronectin in severely burned patients. Burns 1996; 22: 295–297.
Baluna, R, Sausville, E, Stone, MJ, Stetler-Stevenson, MA, Uhr, J, Vitetta, E. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. Clin Cancer Res 1996; 2: 1705–1711.
Bjermer, L, Hallgren, R, Nilsson, K, Franzen, L, Sandstrom, B, Henriksson, R. Radiation-induced increase in hyaluronan and fibronectin in bronchoalveolar lavage fluid from breast cancer patients is suppressed by smoking. Eur Respir J 1992; 5: 785–790.
Barthelemy-Brichant, N, Bosquée, L, Cataldo, D et al. Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 758–767.
Resnikoff, M, Brien, T, Vincent, PA et al. Lung matrix incorporation of plasma fibronectin reduces vascular permeability in postsurgical bacteremia. Am J Phys 1999; 277: L749–L759.
Cox, JD, Stetz, J, Pajak, TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31; 1341–1346.
Shanker, G, Olson, D, Bone, R, Sawhney, R. Regulation of extracellular matrix proteins by transforming growth factor β1 in cultured pulmonary endothelial cells. Cell Biol Int 1999; 23: 61–72.
Nishioka, A, Ogawa, Y, Inomata, T, Maeda, T, Seguchi, H. Fibronectin expression in cancer tissues from patients undergoing radiation therapy. Histol Histopath 1993; 8: 457–462.